ClinicalTrials.Veeva

Menu

Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease. Open-label, Single-center Randomized Study (CB-PRP-TRAC1)

I

Institute of Hospitalization and Scientific Care (IRCCS)

Status

Enrolling

Conditions

Randomised Clinical Trial
Cord Blood
Penile Curvature
Penile Injection Therapy
Peyronie Disease
PRP Injection

Treatments

Procedure: Injection

Study type

Interventional

Funder types

Other

Identifiers

NCT07010900
CB-PRP-TRAC1

Details and patient eligibility

About

The goal of this clinical trial is to learn if Platelet-Rich Plasma Injections from Cord Blood (CB-PRP) is useful in Peyronie disease.

The primary goal is evaluation of patient satisfaction at 1 and 3 months after treatment completion using the PDQ Questionnaire

Secondary Objectives are:

  • Measurement of penile curvature measured with a goniometer with spontaneous erection before and after treatment (1 and 3 months)
  • Measurement of penile length in stretching before and after treatment (1 and 3 months)
  • Evaluation of the improvement in quality of life, through the Short-Form Health Survey 12 (SF-12) health status questionnaire and through the Hospital Anxiety and Depression Scale (HADS)

Participants will be randomized in two groups:

  • penile extender alone
  • penile extender + CB PRP injection (1 injection every 15 days - 3 in totalinjections)

Enrollment

42 estimated patients

Sex

Male

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with Peyronie's Disease (IPP) Penile curvature greater than 30 degrees (autophotography in erection with goniometer measurement) Patients candidates for penile traction Age: 18-75 years Good health conditions Preserved erection (IIEF >20) Complete blood count with differential and coagulation within the normal range (platelets between 150,000 and 450,000 μL) HIV, HCV, and HbsAg negative The fertile partner of the patient randomized to the experimental group must use an acceptable highly effective contraceptive method (oral contraceptives, intrauterine device, abstinence, vasectomized partner) for the entire duration of the study Informed consent to the study

Exclusion criteria

Coagulopathies, platelet disorders Major active infections Previous penile surgery (excluding circumcision and condyloma removal) Previous infiltrative therapy or penile traction treatment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

42 participants in 2 patient groups

Penile extender
No Intervention group
Description:
routine treatment with medical device
CB-PRP Injection
Experimental group
Description:
experimental arm
Treatment:
Procedure: Injection

Trial contacts and locations

1

Loading...

Central trial contact

Franco Gadda, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems